What is your target or goal lipoprotein (a) level for patients on PCSK9 inhibitors for either primary or secondary prevention?   

Let me compliment the clinician who submitted the question because he/she measured lipoprotein (a) [Lp(a)] in the first place. Lp(a) was first described in 1964, but its contribution to atherosclerotic vascular disease risk has only recently attracted widespread attention. Part of that attention is ...

Agree completely. Currently there is not a specified target for Lp(a). We do know that in addition to potent LDL/apoB lowering, the PCSK9 inhibitors lower Lp(a) by about 20-25%. So for those patients with elevated Lp(a) and residual ASCVD risk, PSCK9 inhibition is a reasonable option to lower Lp(a) ...